Abstract: A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group optionally substituted with a hydroxyl group, or are combined to represent ethylene group. However, a compound in which R1 is a hydrogen atom or a methyl group and R2a and R2b are hydrogen atoms is excluded].

Abstract: To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.

Abstract: A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group optionally substituted with a hydroxyl group, or are combined to represent ethylene group. However, a compound in which R1 is a hydrogen atom or a methyl group and R2a and R2b are hydrogen atoms is excluded].

Abstract: Compounds expressed by the following general formula (1), [wherein, R01 and R02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

Abstract: A vitamin D3 derivative expressed by the following general formula (1) [wherein, R is a hydrogen atom or a methyl group, and A is a single bond, —CH2—, —CH?CH—, —CH2—CH?CH—, —CH?CH—CH?CH—, —C?C— or —CH2—C?C—; and a compound in which R is an hydrogen atom, A is —CH2—, the steric configuration at the 1-position is (S)-configuration, and the steric configuration at the 3-position is (R)-configuration is excluded] or a pharmaceutically permissible solvate thereof. The compound can be an effective ingredient of a treating agent for osteoporosis, malignant tumor, psoriasis, hyperparathyroidism, an inflammatory respiratory disease, rheumatoid arthritis, growth onset type diabetes mellitus, hypertension, alopecia, acne, dermatitis, hypercalcemia or Paget's disease of bone.

Abstract: An agent for suppressing the production of parathyroid hormone and a remedy for hyperparathyroidism containing a vitamin D3 derivative described by the following general formula (1) [in the formula, m is an integer of from 1 to 3, q is an integer of from 0 to 3, r is an integer of from 0 to 3 and X is carbon atom or oxygen atom, provided that 1?q+r?3] as an active ingredient.

Abstract: Compounds expressed by the following general formula (1), [wherein, R01 and R02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)]. The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

Abstract: Compounds expressed by the following general formula (1), [wherein, R01 and R02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formula (1-5)]. The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

Abstract: To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist.

Abstract: To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.

Abstract: Compounds expressed by the following general formula (1), [wherein, R01 and R02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)]. The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

Abstract: Compounds expressed by the following general formula (1), The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension; alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

Abstract: Compounds expressed by the following general formula (1), 1

Abstract: Compounds expressed by the following general formula (1), 1

Abstract: Compounds expressed by the following general formula (1), 1

Abstract: Compounds expressed by the following general formula (1), 1

Abstract: Provided are vitamin D.sub.3 derivatives expressed by the following general formula [1] ##STR1## [wherein, R.sub.1 and R.sub.2 are each a hydrogen atom, a trialkylsilyl group, an acetyl group, a methoxymethyl group, or a tetrahydropyranyl group; R.sub.3 and R.sub.4 are each a hydrogen atom, a hydroxyl group, an acyloxy group, an alkyloxy group, an alkylthio group or an alkyl group which is optionally substituted; R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each a hydrogen atom, a hydroxyl group, an alkyl group or an acyloxy group; R.sub.9 is a hydrogen atom, a hydroxyl group, an alkyl group or an alkylthio group; R.sub.10 is a hydrogen atom, an alkyl group or an alkyloxy group; A and B are each a hydrogen atom, a hydroxyl group, or together express a single bond; X and Y express a carbonyl oxygen, or one of them is a hydrogen atom and the other is a hydroxyl group or an acyloxy group; n is an integer of 0 to 2; m is an integer of 0 to 2], and a method for manufacturing the derivatives.

Abstract: The present invention relates to a method of controlling the concentration of calcium in the serum of warm-blooded animals characterized by the administration of a pharmaceutically effective amount of 25-hydroxyvitamin D.sub.3 -26,23-lactones expressed by the following formula (I) ##STR1## wherein R indicates a hydrogen atom or a hydroxyl group and X indicates --O-- or --O--O--, to warm-blooded animals, and a pharmaceutical composition to be used for controlling the concentration of calcium in the serum of warm-blooded animals which comprises 25-hydroxyvitamin D.sub.3 -26,23-lactones expressed by the above-mentioned formula (I) and a pharmaceutically acceptable carrier.25-hydroxyvitamin D.sub.3 -26,23-lactones are desirably used especially for the treatment or prevention of the diseases resulting from the high calcium levels in the serum.

Abstract: Novel 1.alpha.-hydroxy-24-dehydrovitamin D.sub.3 and its hydroxyl-protected derivatives; novel 1.alpha.-hydroxy-24-dehydroprevitamin D.sub.3 and its hydroxyl-protected derivatives; and novel 1.alpha.,3.beta.-dihydroxycholesta-5,7,24-triene or its hydroxyl-protected derivatives which are key intermediates for preparing the aforesaid compounds. Novel processes for preparing these compounds are also provided. 1.alpha.-Hydroxy-24-dehydrovitamin D.sub.3 has a pharmacological action of controlling the calcium metabolism of warm-blooded animals, and is useful as a prophylactic or therapeutic pharmaceutical for vitamin D deficient disease and related diseases.